Omega Therapeutics Announces Updates to its Board of Directors
Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed...
News
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development...
StateHouse Launches Intercanopy Lighting Validation Study
Commercial cannabis cultivator partners with other growers, Grow Light Design and The Cannabis Research Coalition to examine the impact of...
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters...
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Topline Results Expected 1H 2024WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the...
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
19.3 month significant survival difference for CNM-Au8® treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over...
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives...
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed...
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD)...
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused...
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Maximizing global leadership of SYFOVRE in geographic atrophy (GA)Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3GFocusing...
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the...
Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary
Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary Castellum, Inc. (NYSE-American: CTM) (“Castellum”)...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of...
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Bioventure Bioventure logo Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureAlvotech (NASDAQ:...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureREYKJAVIK, Iceland and DUBAI,...